- FLI-06
-
- $30.00
-
2026-05-29
- CAS:313967-18-9
- Purity: 99.81%
- Supply Ability: 10g
|
| Product Name: | FLI-06 | | Synonyms: | FLI-06;1,4,5,6,7,8-Hexahydro-2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-3-quinolinecarboxylic acid cyclohexyl ester;1,4,5,6,7,8-Hexahydro-2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-3-quinolinecarboxylic acid cyclohexyl ester FLI-06;3-QUINOLINECARBOXYLIC ACID, 1,4,5,6,7,8-HEXAHYDRO-2,7,7-TRIMETHYL-4-(4-NITROPHENYL)-5-OXO-, CYCLOHEXYL ESTER;FLI-06, 98%, a notch signaling and the early secretory pathway inhibitor;FLI-06 |FLI06;Cyclohexyl 1,4,5,6,7,8-hexahydro-2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-3-quinolinecarboxylate;CS-1434 | | CAS: | 313967-18-9 | | MF: | C25H30N2O5 | | MW: | 438.52 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 313967-18-9.mol |  |
| | FLI-06 Chemical Properties |
| Melting point | 199-202oC | | Boiling point | 597.5±50.0 °C(Predicted) | | density | 1.25±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: soluble5mg/mL, clear (warmed) | | pka | 0.78±0.70(Predicted) | | form | powder | | color | white to beige | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 week. | | InChI | 1S/C25H30N2O5/c1-15-21(24(29)32-18-7-5-4-6-8-18)22(16-9-11-17(12-10-16)27(30)31)23-19(26-15)13-25(2,3)14-20(23)28/h9-12,18,22,26H,4-8,13-14H2,1-3H3 | | InChIKey | SWWVFYHSSOWZMF-UHFFFAOYSA-N | | SMILES | [N+](=O)([O-])c1ccc(cc1)C2C3=C(NC(=C2C(=O)OC4CCCCC4)C)CC(CC3=O)(C)C |
| RIDADR | 3077 | | WGK Germany | 3 | | HS Code | 29339900 | | Storage Class | 11 - Combustible Solids |
| | FLI-06 Usage And Synthesis |
| Description | FLI-06 (313967-18-9) was discovered in a screen designed to monitor the trafficking and processing of a ligand-independent Notch-enhanced GFP reporter. It was found to disrupt the Golgi apparatus in a manner distinct from that of brefeldin A. It inhibited general secretion at a step before exit from the ER which was accompanied by a tubule-to-sheet morphological transition of the ER. Thus FLI-06 is the first small molecule acting at such an early stage in secretory traffic.1 | | Uses | FLI-06 is a novel inhibitor of Notch signalling and the early secretory pathway. | | Background | The dihydropyridine FLI-06 is a Notch pathway inhibitor with an EC50 of 2.5 mM. Signaling through Notch transmembrane receptor proteins plays an important role in cell-fate decisions; aberrant Notch activity can result in cancer and other developmental disorders. FLI-06 acts at an early stage in the secretory pathway, disrupting the Golgi and inhibiting general secretion before exit from the endoplasmic reticulum. Studies show that FLI-06 suppresses both the mRNA and protein expression of Notch receptor and Notch targeted genes. FLI-06 treatment of tongue cancer cells inhibits Notch signaling activation, decreasing cell proliferation, blocking cell cycle arrest, and inducing apoptosis. FLI-06 inhibited tumor growth and increased cell apoptosis in a xenograft mouse model, suggesting that FLI-06 is a potential chemotherapeutic agent for the clinical treatment of tongue tumors. Additional studies showed that FLI-06 inactivated Notch signaling and suppressed malignant functions in lung adenocarcinoma and esophageal squamous cell carcinoma. | | References | [1] ANDREAS KRÄMER. Small molecules intercept Notch signaling and the early secretory pathway[J]. Nature chemical biology, 2013, 9 11: 731-738. DOI:10.1038/nchembio.1356 |
| | FLI-06 Preparation Products And Raw materials |
|